MedWatch

Zealand Pharma ends recruitment for phase III study of glepaglutide

A sufficient number of patients have been enrolled for Zealand Pharma's phase III trial with glepaglutide, which is a potential treatment of short bowel syndrome (SBS).

Photo: Zealand Pharma / PR

All of the necessary patients have been found and recruited for a phase III study of glepaglutide, which is a potential treatment of short bowel syndrome (SBS), Zealand Pharma announces in a press release on Thursday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs